First Marketing Authorization secured by Venus Remedies for Plerixafor in any market Advances the company's shift into higher value specialty injectables across regulated markets Plerixafor is a stem cell mobilization therapy used in autologous transplantation for multiple myeloma and non-Hodgkin lymphoma Venus Remedies Limited (NSE:
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), among the world’s leading fixed-dosage injectable manufacturers, has secured the marketing authorization from the Indonesian regulatory authority
